Keros Therapeutics, Inc. (KROS): restructuring charge — Keros ends PAH program, cuts 45% of staff, expects $17M annual savings

Keros Therapeutics, Inc.

TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.
Workforce reduced ~45% to 85 employees; one-time severance charges of ~$3.2M in Q2 2025.
Annualized cost savings of ~$17M expected; restructuring substantially complete by Q4 2025.
Strategic alternatives review ongoing; preliminary update to be provided by June 9, 2025.

item 2.05 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Keros Therapeutics, Inc. announced a restructuring with charges of approximately $3.2 million (approximately 45%).

Type: restructuring
Charge: approximately $3.2 million
Headcount: approximately 45%

Exact text from the filing

These plans were communicated to affected employees on May 29, 2025. The Company expects to incur one-time cash charges associated with the Reorganization of approximately $3.2 million related to employee severance payments and related costs, which are expected to be expensed in the second quarter of 2025. In addition, the Company has committed to pay one-time

View on SEC.gov

Browse all restructurings & charges →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-25-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.